

Think of 8



Children and Community Crisis

Our Non-Profit Partner Jeevan Biosciences, Inc. (JBI) has teamed up with Community & Children In Crisis, Inc. (CCC) on this very important initiative. CCC is a charitable organization dedicated to working with children, families, and their communities. Working with CCC allow them to provide JBI with funding for breakthrough cancer research. Through the generosity of private donors, the cost of CCC general operations are covered. That means 100% of your money will go straight to cancer research!

Jeevan Biosciences Inc. is establishing the very first cancer stem cell library for medical research. We want to see women of different ancestries beat breast cancer by creating treatment that is specific for the patient and not just for treating breast cancer.

At Jeevan Biosciences Inc., we are on the forefront of bringing ancestry and drug development together. We embrace genetic diversity through our research. Visit jeevanbiosciences.com, and support our cause today.

Our Story

Did you know that one out of eight women are at risk of death caused by breast cancer?

Overarching Challenge:

Breast cancer is one of the most common cancers among American women. Breast cancer is also a global problem, accounting for nearly a quarter of all cancers in women. It is estimated that globally, 1.7 million women are diagnosed with breast cancer annually. About 1 in 8 (12%) women in the US will develop invasive breast cancer during their lifetime. The chance that breast cancer will be responsible for a woman's death is about 1 in 36 (about 3%). Genetic diversity is the determining factor behind why some women are more likely to receive a diagnosis of breast cancer, while others are more likely to die from breast cancer. In addition, studies have demonstrated that some women tend to have a more advanced stage of disease at the time of diagnosis.

Genetic diversity is a contributing factor in why some women develop a more aggressive and deadly form of the disease, commonly referred to as Triple-negative breast cancer (TNBC). TNBCs have a relapse pattern that is very different from other breast cancers, and many hypothesize that there are subgroups of patients with treatment-resistant TNBC, which is initiated and maintained by cancer stem cells. Although breast cancers are very different and their growth can vary from person to person, the majority of women with breast cancer still receive the same treatment, as though the breast cancers were all the same. Despite decades

of advancement in breast cancer research, there are no FDA approved therapies for triple negative breast cancer. The battle against this disease is still ongoing.

The overarching challenge is the issue of efficacy regarding drug treatment of women with TNBC. To address the issues of efficacy, drug development, recurrence, and metastasis of TNBC, Jeevan Biosciences, Inc (JBI) has developed a cancer stem cell (CSC) repository. This CSC repository is composed of primary cells that were isolated from patient breast cancer core biopsies. However, there is a need to expand the repository to represent the current demographic of women in the US, who are diagnosed with TNBC. CSCs taken from TNBC biopsies are unique, and can be used for drug discovery and basic research into which drugs work better for people of specific genetic backgrounds and heritage. These cells can help predict patient outcomes and responses to radiation, chemotherapy, and targeted therapeutics, as well as predict outcomes of long term treatments. Therefore JBI, requires funding for the expansion of its CSC repository.

Currently, there is not a human, cell model or animal model that represents the genetic diversity seen in Americans that are diagnosed with TNBC. The expansion of this CSC repository will create the only CSC repository that represents the genetic diversity of the current population that is diagnosed with TNBC in America. This will allow for the development of more effective drug treatments, save lives, and improve the quality of life for those diagnosed with TNBC. JBI believes that the technology and know-how developed from creating a CSC repository for breast cancer will also help in creating CSC repositories for other types of cancers.